Featured Research

from universities, journals, and other organizations

Yeast Research Targets Drug Resistance Battle

Date:
September 18, 2002
Source:
University Of Toronto
Summary:
Evolution of a much-maligned yeast shows that drug resistance is a predictable outcome of exposure to drugs, say University of Toronto botanists. Microbes that survive drug treatment often become drug-resistant. Researchers in the labs of Professors Jim Anderson and Linda Kohn of botany have determined how this happens by studying the yeast Candida albicans and its genetic changes when exposed to drugs.

Evolution of a much-maligned yeast shows that drug resistance is a predictable outcome of exposure to drugs, say University of Toronto botanists. Microbes that survive drug treatment often become drug-resistant. Researchers in the labs of Professors Jim Anderson and Linda Kohn of botany have determined how this happens by studying the yeast Candida albicans and its genetic changes when exposed to drugs. "Ultimately, our findings could lead to the development of companion drugs that target these sets of genes, delaying or preventing the evolution of resistance to the therapeutic drug," says doctoral student Leah Cowen, the study's lead author.

Researchers grew over 330 generations of the yeast - a common inhabitant of healthy humans that causes thrush, diaper rash and infections in women as well as life-threatening infections in immuno-compromised individuals - in the presence of the widely prescribed anti-fungal drug fluconazole. Drug resistance increased as the researchers had predicted. While they saw expected changes to the molecular pumps (which remove a variety of drugs from cells), they also noted changes in hundreds of genes. More surprisingly, they found the altered genes displayed three distinct patterns - a finding replicated in patient samples. Recognizing these patterns will make it easier for scientists to target drug therapy, Cowen says.

Funding for the research, published in Proceedings of the National Academy of Sciences, was provided by the Natural Sciences and Engineering Research Council of Canada. The drug fluconazole was supplied by Pfizer Inc.


Story Source:

The above story is based on materials provided by University Of Toronto. Note: Materials may be edited for content and length.


Cite This Page:

University Of Toronto. "Yeast Research Targets Drug Resistance Battle." ScienceDaily. ScienceDaily, 18 September 2002. <www.sciencedaily.com/releases/2002/09/020918064224.htm>.
University Of Toronto. (2002, September 18). Yeast Research Targets Drug Resistance Battle. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2002/09/020918064224.htm
University Of Toronto. "Yeast Research Targets Drug Resistance Battle." ScienceDaily. www.sciencedaily.com/releases/2002/09/020918064224.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins